Ba da daɗewa ba bayan Abbott ya kammala isar da gwaje-gwajen antigen na gaggawa miliyan 150 ga gwamnatin tarayya don yaɗuwar cutar ta COVID-19, masu bincike daga Cibiyar Kula da Cututtuka da Cututtuka (CDC) Kada ku kasance masu kamuwa da cutar Kusan kashi biyu cikin uku na cututtukan asymptomatic.
An gudanar da binciken tare da jami'an kiwon lafiya na gida a gundumar Pima, Arizona, kewaye da garin Tucson.Binciken ya tattara samfurori guda biyu daga manya da matasa fiye da 3,400.An gwada swab ɗaya ta amfani da gwajin Abbott's BinaxNOW, yayin da aka sarrafa ɗayan ta amfani da gwajin ƙwayoyin cuta na PCR.
Daga cikin waɗanda suka gwada inganci, masu binciken sun gano cewa gwajin antigen daidai ya gano cututtukan COVID-19 a cikin 35.8% na waɗanda ba su ba da rahoton wata alama ba, kuma 64.2% na waɗanda suka ce ba su da lafiya a cikin makonni biyu na farko.
Koyaya, nau'ikan gwaje-gwajen coronavirus daban-daban ba za a iya tsara su daidai iri ɗaya ba a cikin yanayi da yanayi daban-daban, kuma suna iya bambanta gwargwadon abubuwan da aka bincika da lokacin amfani.Kamar yadda Abbott (Abbott) ya nuna a cikin wata sanarwa, gwaje-gwajensa sun yi kyau wajen gano mutanen da suka fi kamuwa da cututtuka da cututtuka (ko samfuran da ke ɗauke da ƙwayoyin cuta masu rai).
Kamfanin ya nuna cewa "BinaxNOW yana da kyau sosai wajen gano yawan masu kamuwa da cuta," wanda ke nuna mahalarta masu kyau.Gwajin ya gano kashi 78.6% na mutanen da zasu iya noma kwayar cutar amma asymptomatic da kashi 92.6% na mutanen da ke da alamun cutar.
Gwajin immunoassay gaba ɗaya yana ƙunshe ne a cikin ɗan ƙaramin takarda mai girman katin kiredit tare da saka swab ɗin auduga tare da gauraye da ɗigo a cikin kwalabe na reagent.Jerin layukan kala sun bayyana don samar da sakamako mai kyau, mara kyau ko mara inganci.
Binciken CDC ya gano cewa gwajin BinaxNOW shima ya fi daidai.Daga cikin mahalarta alamomin da suka ba da rahoton alamun cutar a cikin kwanaki 7 da suka gabata, hankali shine 71.1%, wanda shine ɗayan izinin amfani da gwajin da FDA ta amince.A lokaci guda, bayanan asibiti na Abbott sun nuna cewa ji na rukunin marasa lafiya ɗaya shine 84.6%.
Kamfanin ya ce: "Mahimmanci ma, waɗannan bayanan sun nuna cewa idan mai haƙuri ba shi da alamun bayyanar cututtuka kuma sakamakon ya kasance mara kyau, BinaxNOW zai ba da amsar daidai 96.9% na lokaci," kamfanin yana nufin ƙayyadaddun ma'auni na gwajin.
Cibiyar Kula da Cututtuka da Cututtuka ta Amurka (CDC) ta amince da kimantawar, tana mai cewa saurin gwajin antigen yana da ƙarancin sakamako mai inganci (ko da yake akwai iyakoki idan aka kwatanta da gwajin PCR da ke gudanar da dakin gwaje-gwaje) saboda sauƙin amfani da sauri. sarrafa Lokaci da ƙananan farashi har yanzu muhimmin kayan aikin tantancewa ne.Production da kuma aiki.
Masu binciken sun ce: "Mutanen da suka san sakamako mai kyau a cikin mintuna 15 zuwa 30 za a iya keɓe su cikin sauri kuma za su iya fara tuntuɓar tuntuɓar tun da wuri kuma sun fi tasiri fiye da dawo da sakamakon gwajin bayan 'yan kwanaki.""Gwajin Antigen ya fi tasiri."Saurin juyowa zai iya taimakawa iyakance yaɗuwar ta hanyar gano mutanen da suka kamu da cutar da za a keɓe cikin sauri, musamman idan aka yi amfani da su azaman wani ɓangare na dabarun gwaji. "
Abbott ya fada a watan da ya gabata cewa yana shirin fara ba da gwaje-gwajen BinaxNOW kai tsaye don siyan kasuwanci don amfani a gida da kan layi ta hanyar masu ba da lafiya, kuma yana shirin isar da wasu gwaje-gwajen BinaxNOW miliyan 30 a karshen Maris, da kuma wani miliyan 90 zuwa A karshen watan Yuni.
Lokacin aikawa: Fabrairu-25-2021